These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17447720)

  • 1. Prevention of acute mountain sickness in Nepali porters: a controlled trial.
    Ghimire LV; Pun M
    Wilderness Environ Med; 2007; 18(1):72-3; author reply 73-4. PubMed ID: 17447720
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial.
    Hillenbrand P; Pahari AK; Soon Y; Subedi D; Bajracharya R; Gurung P; Lal BK; Marahatta R; Pradhan S; Rai D; Sharma S;
    Wilderness Environ Med; 2006; 17(2):87-93. PubMed ID: 16805144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incidence, prevention and therapy of acute mountain sickness].
    Oelz O
    Schweiz Med Wochenschr; 1982 Apr; 112(14):492-5. PubMed ID: 7079685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute mountain sickness prophylaxis: knowledge, attitudes, & behaviours in the Everest region of Nepal.
    Kilner T; Mukerji S
    Travel Med Infect Dis; 2010 Nov; 8(6):395-400. PubMed ID: 21112541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of acute mountain sickness.
    Ramsay LE
    Lancet; 1977 Mar; 1(8010):540-1. PubMed ID: 65630
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).
    Gertsch JH; Basnyat B; Johnson EW; Onopa J; Holck PS
    BMJ; 2004 Apr; 328(7443):797. PubMed ID: 15070635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group).
    Basnyat B; Holck PS; Pun M; Halverson S; Szawarski P; Gertsch J; Steif M; Powell S; Khanal S; Joshi A; Shankar R; Karambay J; Alexander HD; Stone A; Morrissey C; Thompson BH; Farrar J;
    Wilderness Environ Med; 2011 Mar; 22(1):15-22. PubMed ID: 21377114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological prevention of acute mountain sickness. Many climbers and trekkers find acetazolamide 500 mg/day to be useful.
    Hackett P
    BMJ; 2001 Jan; 322(7277):48; author reply 49. PubMed ID: 11141167
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological prevention of acute mountain sickness. Same ascent rates must be used to assess effectiveness of different doses of acetazolamide.
    Bärtsch P; Schneider M
    BMJ; 2001 Jan; 322(7277):48-9. PubMed ID: 11141168
    [No Abstract]   [Full Text] [Related]  

  • 10. Acetazolamide prophylaxis for acute mountain sickness.
    Drug Ther Bull; 1987 Jun; 25(12):45-7. PubMed ID: 3608821
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetazolamide in prevention of acute mountain sickness: a double-blind controlled cross-over study.
    Greene MK; Kerr AM; McIntosh IB; Prescott RJ
    Br Med J (Clin Res Ed); 1981 Sep; 283(6295):811-3. PubMed ID: 6794709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding of Altitude Illness and Use of Pharmacotherapy Among Trekkers and Porters in the Annapurna Region of Nepal.
    Havryliuk T; Acharya B; Caruso E; Cushing T
    High Alt Med Biol; 2015 Sep; 16(3):236-43. PubMed ID: 26244262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpine travel. Mountain sickness, the unwelcome companion.
    Smart J; Hunter D
    Med J Aust; 1984 Dec 8-22; 141(12-13):792-5. PubMed ID: 6503782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetazolamide in prevention of acute mountain sickness.
    McIntosh IB; Prescott RJ
    J Int Med Res; 1986; 14(5):285-7. PubMed ID: 3533677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose acetylsalicylic Acid analog and acetazolamide for prevention of acute mountain sickness.
    Basnyat B; Gertsch JH; Holck PC
    High Alt Med Biol; 2008; 9(4):349; author reply 351-2. PubMed ID: 19115924
    [No Abstract]   [Full Text] [Related]  

  • 16. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.
    Basnyat B; Gertsch JH; Holck PS; Johnson EW; Luks AM; Donham BP; Fleischman RJ; Gowder DW; Hawksworth JS; Jensen BT; Kleiman RJ; Loveridge AH; Lundeen EB; Newman SL; Noboa JA; Miegs DP; O'Beirne KA; Philpot KB; Schultz MN; Valente MC; Wiebers MR; Swenson ER
    High Alt Med Biol; 2006; 7(1):17-27. PubMed ID: 16544963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the incidence and understanding of altitude illness between porters and trekkers in the Solu Khumbu Region of Nepal.
    Newcomb L; Sherpa C; Nickol A; Windsor J
    Wilderness Environ Med; 2011 Sep; 22(3):197-201. PubMed ID: 21962045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetazolamide and high altitude diseases.
    Bradwell AR; Wright AD; Winterborn M; Imray C
    Int J Sports Med; 1992 Oct; 13 Suppl 1():S63-4. PubMed ID: 1483796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetazolamide for the prevention of acute mountain sickness--a systematic review and meta-analysis.
    Ritchie ND; Baggott AV; Andrew Todd WT
    J Travel Med; 2012; 19(5):298-307. PubMed ID: 22943270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up.
    Gaillard S; Dellasanta P; Loutan L; Kayser B
    High Alt Med Biol; 2004; 5(4):410-9. PubMed ID: 15671630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.